Urology practice · 2026
Utility of 18F-Flotufolastat Positron Emission Tomography/Computed Tomography Imaging in High-Risk Prostate Cancer in a Real-World Setting.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Taylor Zachariah, Meyer Kayla, Stollman Nachum, Zinar Cheryl, Belkoff Laurence, Zeltser Ilia
Аннотация
INTRODUCTION: This investigator-initiated, prospective, low-intervention, phase 3 study evaluated the clinical utility of prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/CT imaging with 18F-flotufolastat (formerly 18F-rhPSMA-7.3) in men with newly diagnosed high-risk prostate cancer (PCa) and negative conventional imaging. The primary end point was the rate of clinical upstaging and its effect on subsequent management.
METHODS: A total of 113 treatment-naïve men meeting National Comprehensive Cancer Network high-risk criteria were enrolled; 110 underwent PSMA PET/CT with 18F-flotufolastat. Before imaging, all patients had negative conventional staging, as determined by bone scan and CT or MRI. Imaging was performed 50 to 70 minutes post injection of 8 mCi ± 20% 18F-flotufolastat. The results were interpreted by board-certified nuclear medicine physicians trained in PSMA imaging.
RESULTS: 18F-flotufolastat identified extraprostatic disease in 36 of 110 patients (32.7%). Among them, 15 of 36 (41.7%) had isolated regional lymph node (N1) involvement, while 21 of 36 (58.3%) demonstrated distant metastatic (M1) disease. Of the patients who were upstaged, 34 of 36 patients (94.4%) had a change in their treatment plan. The most common treatment intensification included the addition of an androgen receptor inhibitor and expanded radiotherapy fields (50.0%). Furthermore, 34.3% received up-front chemotherapy alongside an androgen receptor inhibitor and radiation. A minority (8.6%) proceeded with radical prostatectomy as a first step of a multimodality approach.
CONCLUSIONS: PSMA PET/CT with 18F-flotufolastat led to clinical upstaging in nearly one-third of men with high-risk PCa and negative conventional imaging, resulting in significant treatment change in most patients. These findings support the integration of PSMA-targeted imaging into initial staging pathways for men with high-risk PCa.
METHODS: A total of 113 treatment-naïve men meeting National Comprehensive Cancer Network high-risk criteria were enrolled; 110 underwent PSMA PET/CT with 18F-flotufolastat. Before imaging, all patients had negative conventional staging, as determined by bone scan and CT or MRI. Imaging was performed 50 to 70 minutes post injection of 8 mCi ± 20% 18F-flotufolastat. The results were interpreted by board-certified nuclear medicine physicians trained in PSMA imaging.
RESULTS: 18F-flotufolastat identified extraprostatic disease in 36 of 110 patients (32.7%). Among them, 15 of 36 (41.7%) had isolated regional lymph node (N1) involvement, while 21 of 36 (58.3%) demonstrated distant metastatic (M1) disease. Of the patients who were upstaged, 34 of 36 patients (94.4%) had a change in their treatment plan. The most common treatment intensification included the addition of an androgen receptor inhibitor and expanded radiotherapy fields (50.0%). Furthermore, 34.3% received up-front chemotherapy alongside an androgen receptor inhibitor and radiation. A minority (8.6%) proceeded with radical prostatectomy as a first step of a multimodality approach.
CONCLUSIONS: PSMA PET/CT with 18F-flotufolastat led to clinical upstaging in nearly one-third of men with high-risk PCa and negative conventional imaging, resulting in significant treatment change in most patients. These findings support the integration of PSMA-targeted imaging into initial staging pathways for men with high-risk PCa.